**Supplementary Figure 1.** Forest plot of treatment differences on the standard normal scale for ACR response at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).

ACR = American College of Rheumatology; bDMARD = biologic disease-modifying anti-rheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PsA = psoriatic arthritis; QxW = every x weeks; SC = subcutaneously.
Supplementary Figure 2. Forest plot of odds ratios for PsARC at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).

bDMARD = biologic disease-modifying anti-rheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PsA = psoriatic arthritis; PsARC = Psoriatic Response Criteria; QxW = every x weeks; SC = subcutaneously.
**Supplementary Figure 3.** Forest plot of treatment differences on the standard normal scale for PASI at weeks 12–16 among bDMARD-naïve patients with active PsA (ixekizumab 80 mg Q4W as the reference).

- **bDMARD** = biologic disease-modifying anti-rheumatic drug; **BID** = twice daily; **BIW** = twice weekly; **IV** = intravenously; **PASI** = Psoriasis Area and Severity Index; **PsA** = psoriatic arthritis; **QxW** = every x weeks; **SC** = subcutaneously.